Vor Biopharma Inc (VOR) concluded trading on Thursday at a closing price of $0.16, with 16.33 million shares of worth about $2.61 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.49% during that period and on May 08, 2025 the price saw a loss of about -70.12%. Currently the company’s common shares owned by public are about 124.78M shares, out of which, 76.79M shares are available for trading.
Stock saw a price change of -75.79% in past 5 days and over the past one month there was a price change of -70.91%. Year-to-date (YTD), VOR shares are showing a performance of -85.59% which decreased to -90.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.49 but also hit the highest price of $1.87 during that period. The average intraday trading volume for Vor Biopharma Inc shares is 283.49K. The stock is currently trading -75.10% below its 20-day simple moving average (SMA20), while that difference is down -78.52% for SMA50 and it goes to -82.81% lower than SMA200.
Vor Biopharma Inc (NASDAQ: VOR) currently have 124.78M outstanding shares and institutions hold larger chunk of about 42.99% of that.
The stock has a current market capitalization of $19.98M and its 3Y-monthly beta is at -0.22. It has posted earnings per share of -$1.70 in the same period. It has Quick Ratio of 5.19 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VOR, volatility over the week remained 29.15% while standing at 14.49% over the month.
Stock’s fiscal year EPS is expected to rise by 46.37% while it is estimated to increase by 2.36% in next year. EPS is likely to grow at an annualized rate of 26.68% for next 5-years, compared to annual growth of -38.02% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on July 26, 2022 offering an Outperform rating for the stock and assigned a target price of $18 to it. Coverage by Goldman stated Vor Biopharma Inc (VOR) stock as a Neutral in their note to investors on April 27, 2022, suggesting a price target of $6 for the stock. On December 17, 2021, H.C. Wainwright Initiated their recommendations, while on December 03, 2021, Robert W. Baird Initiated their ratings for the stock with a price target of $38. Stock get an Outperform rating from Oppenheimer on December 02, 2021.
